BACKGROUND: A study was undertaken to evaluate Chlamydia pneumoniae chronic infection, other respiratory infections, and functional impairment in patients with chronic bronchitis (stage 1) and to examine chronic C pneumoniae infection, rate of acute exacerbations of chronic bronchitis, and rate of C pneumoniae eradication following antibiotic treatment (stage 2). METHODS: In the stage 1 study respiratory specimens from 42 patients with steady state chronic bronchitis were analysed for Gram staining, sputum culture, and C pneumoniae DNA detection by nested touchdown polymerase chain reaction (PCR). On the basis of the results of stage 1, a second population of 141 consecutive patients with steady state mild to moderate chronic bronchitis (FEV(1) >or=50% predicted) was studied. On admission, at regular intervals, and at exacerbation all patients underwent serological testing for C pneumoniae (microimmunofluorescence) and a nested touchdown PCR to detect C pneumoniae DNA was performed on peripheral blood mononuclear cells (PBMCs). Patients were assessed over a 12 month period. Information regarding the previous 12 months was taken from medical records. RESULTS: Chronic colonisation of the sputum with C pneumoniae was significantly associated with lower FEV(1) and greater airway bacterial colonisation. On admission to the stage 2 study, 80 patients were PCR negative and 61 were PCR positive. Over the 2 years a mean (SD) of 1.43 (1.32) acute exacerbations occurred in PCR negative patients and 2.03 (1.21) in PCR positive patients (p<0.01). During the 12 month follow up period 34 PCR positive patients had acute exacerbations and were treated with azithromycin for 6 weeks. Serological evidence of acute C pneumoniae reinfection/reactivation was found in two of the 34 patients. The rate of C pneumoniae DNA clearance from blood following treatment was 29% at follow up. CONCLUSION: Chronic colonisation with C pneumoniae is associated with a higher rate of exacerbations of chronic bronchitis. Long term treatment is required to obtain clearance of the organism from the blood.
BACKGROUND: A study was undertaken to evaluate Chlamydia pneumoniae chronic infection, other respiratory infections, and functional impairment in patients with chronic bronchitis (stage 1) and to examine chronic C pneumoniae infection, rate of acute exacerbations of chronic bronchitis, and rate of C pneumoniae eradication following antibiotic treatment (stage 2). METHODS: In the stage 1 study respiratory specimens from 42 patients with steady state chronic bronchitis were analysed for Gram staining, sputum culture, and C pneumoniae DNA detection by nested touchdown polymerase chain reaction (PCR). On the basis of the results of stage 1, a second population of 141 consecutive patients with steady state mild to moderate chronic bronchitis (FEV(1) >or=50% predicted) was studied. On admission, at regular intervals, and at exacerbation all patients underwent serological testing for C pneumoniae (microimmunofluorescence) and a nested touchdown PCR to detect C pneumoniae DNA was performed on peripheral blood mononuclear cells (PBMCs). Patients were assessed over a 12 month period. Information regarding the previous 12 months was taken from medical records. RESULTS: Chronic colonisation of the sputum with C pneumoniae was significantly associated with lower FEV(1) and greater airway bacterial colonisation. On admission to the stage 2 study, 80 patients were PCR negative and 61 were PCR positive. Over the 2 years a mean (SD) of 1.43 (1.32) acute exacerbations occurred in PCR negative patients and 2.03 (1.21) in PCR positive patients (p<0.01). During the 12 month follow up period 34 PCR positive patients had acute exacerbations and were treated with azithromycin for 6 weeks. Serological evidence of acute C pneumoniae reinfection/reactivation was found in two of the 34 patients. The rate of C pneumoniae DNA clearance from blood following treatment was 29% at follow up. CONCLUSION: Chronic colonisation with C pneumoniae is associated with a higher rate of exacerbations of chronic bronchitis. Long term treatment is required to obtain clearance of the organism from the blood.
Authors: G A Finlay; K J Russell; K J McMahon; E M D'arcy; J B Masterson; M X FitzGerald; C M O'Connor Journal: Thorax Date: 1997-06 Impact factor: 9.139
Authors: G A Finlay; L R O'Driscoll; K J Russell; E M D'Arcy; J B Masterson; M X FitzGerald; C M O'Connor Journal: Am J Respir Crit Care Med Date: 1997-07 Impact factor: 21.405
Authors: L von Hertzen; R Isoaho; M Leinonen; R Koskinen; P Laippala; M Töyrylä; S L Kivelä; P Saikku Journal: Int J Epidemiol Date: 1996-06 Impact factor: 7.196
Authors: L Von Hertzen; H Alakärppä; R Koskinen; K Liippo; H M Surcel; M Leinonen; P Saikku Journal: Epidemiol Infect Date: 1997-04 Impact factor: 2.451
Authors: Arne Egesten; Lena Brandt; Tomas Olsson; Fredrik Granath; Malin Inghammar; Claes-Göran Löfdahl; Anders Ekbom Journal: Lung Date: 2008-03-20 Impact factor: 2.584
Authors: Elina Hakala; Leena Hanski; Hanna Uvell; Teijo Yrjönen; Heikki Vuorela; Mikael Elofsson; Pia Maarit Vuorela Journal: J Antibiot (Tokyo) Date: 2015-05-06 Impact factor: 2.649
Authors: P M Fitch; N M Wheelhouse; P Bowles; M Paterson; D Longbottom; G Entrican; S E M Howie Journal: Clin Exp Immunol Date: 2010-09-14 Impact factor: 4.330
Authors: Claire A Gross; Russell P Bowler; Rebecca M Green; Andrew R Weinberger; Christina Schnell; Hong Wei Chu Journal: BMC Pulm Med Date: 2010-05-14 Impact factor: 3.317